Cargando…
Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia
Clozapine is considered the gold standard for patients with treatment-resistant schizophrenia (TRS) who have previously tried other antipsychotics at adequate doses (two or more, with at least one being atypical). However, despite optimal treatment, a subgroup of TRS patients with what is known as u...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135858/ https://www.ncbi.nlm.nih.gov/pubmed/37189691 http://dx.doi.org/10.3390/biomedicines11041072 |
_version_ | 1785032081026318336 |
---|---|
author | Peitl, Vjekoslav Puljić, Antonia Škrobo, Mislav Nadalin, Sergej Fumić Dunkić, Lidija Karlović, Dalibor |
author_facet | Peitl, Vjekoslav Puljić, Antonia Škrobo, Mislav Nadalin, Sergej Fumić Dunkić, Lidija Karlović, Dalibor |
author_sort | Peitl, Vjekoslav |
collection | PubMed |
description | Clozapine is considered the gold standard for patients with treatment-resistant schizophrenia (TRS) who have previously tried other antipsychotics at adequate doses (two or more, with at least one being atypical). However, despite optimal treatment, a subgroup of TRS patients with what is known as ultra-treatment-resistant schizophrenia (UTRS) fails to respond to clozapine, which occurs in 40–70% of cases. The most common approach to manage UTRS involves augmenting clozapine with pharmacological or non-pharmacological interventions, with a growing body of evidence that supports the use of electroconvulsive therapy (ECT) as an augmenter. This prospective non-randomized 8-week study, which followed the TRIPP Working Group guidelines and is one of few that separate TRS from UTRS, aimed to evaluate the effectiveness of clozapine in TRS patients and the efficacy of ECT augmentation of clozapine in UTRS patients. Patients with TRS were assigned to receive clozapine alone (clozapine group), whereas UTRS patients received bilateral ECT in addition to their current medication regimen (ECT plus clozapine group). The severity of symptoms was evaluated using the Clinical Global Impression Scale (CGI) and Positive and Negative Syndrome Scale (PANSS) at baseline and at the end of the 8-week trial. Both treatment approaches resulted in improved CGI and PANSS scores. The results suggest that both clozapine and ECT are effective treatment options for patients with TRS and UTRS, respectively, and that adherence to guidelines should provide a better frame for future clinical studies. |
format | Online Article Text |
id | pubmed-10135858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101358582023-04-28 Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia Peitl, Vjekoslav Puljić, Antonia Škrobo, Mislav Nadalin, Sergej Fumić Dunkić, Lidija Karlović, Dalibor Biomedicines Article Clozapine is considered the gold standard for patients with treatment-resistant schizophrenia (TRS) who have previously tried other antipsychotics at adequate doses (two or more, with at least one being atypical). However, despite optimal treatment, a subgroup of TRS patients with what is known as ultra-treatment-resistant schizophrenia (UTRS) fails to respond to clozapine, which occurs in 40–70% of cases. The most common approach to manage UTRS involves augmenting clozapine with pharmacological or non-pharmacological interventions, with a growing body of evidence that supports the use of electroconvulsive therapy (ECT) as an augmenter. This prospective non-randomized 8-week study, which followed the TRIPP Working Group guidelines and is one of few that separate TRS from UTRS, aimed to evaluate the effectiveness of clozapine in TRS patients and the efficacy of ECT augmentation of clozapine in UTRS patients. Patients with TRS were assigned to receive clozapine alone (clozapine group), whereas UTRS patients received bilateral ECT in addition to their current medication regimen (ECT plus clozapine group). The severity of symptoms was evaluated using the Clinical Global Impression Scale (CGI) and Positive and Negative Syndrome Scale (PANSS) at baseline and at the end of the 8-week trial. Both treatment approaches resulted in improved CGI and PANSS scores. The results suggest that both clozapine and ECT are effective treatment options for patients with TRS and UTRS, respectively, and that adherence to guidelines should provide a better frame for future clinical studies. MDPI 2023-04-02 /pmc/articles/PMC10135858/ /pubmed/37189691 http://dx.doi.org/10.3390/biomedicines11041072 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Peitl, Vjekoslav Puljić, Antonia Škrobo, Mislav Nadalin, Sergej Fumić Dunkić, Lidija Karlović, Dalibor Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia |
title | Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia |
title_full | Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia |
title_fullStr | Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia |
title_full_unstemmed | Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia |
title_short | Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia |
title_sort | clozapine in treatment-resistant schizophrenia and its augmentation with electroconvulsive therapy in ultra-treatment-resistant schizophrenia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135858/ https://www.ncbi.nlm.nih.gov/pubmed/37189691 http://dx.doi.org/10.3390/biomedicines11041072 |
work_keys_str_mv | AT peitlvjekoslav clozapineintreatmentresistantschizophreniaanditsaugmentationwithelectroconvulsivetherapyinultratreatmentresistantschizophrenia AT puljicantonia clozapineintreatmentresistantschizophreniaanditsaugmentationwithelectroconvulsivetherapyinultratreatmentresistantschizophrenia AT skrobomislav clozapineintreatmentresistantschizophreniaanditsaugmentationwithelectroconvulsivetherapyinultratreatmentresistantschizophrenia AT nadalinsergej clozapineintreatmentresistantschizophreniaanditsaugmentationwithelectroconvulsivetherapyinultratreatmentresistantschizophrenia AT fumicdunkiclidija clozapineintreatmentresistantschizophreniaanditsaugmentationwithelectroconvulsivetherapyinultratreatmentresistantschizophrenia AT karlovicdalibor clozapineintreatmentresistantschizophreniaanditsaugmentationwithelectroconvulsivetherapyinultratreatmentresistantschizophrenia |